Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis

doi:10.1155/2018/5072987

科研成果详情

题名	Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis
作者	Zheng, Peng 1; Liang, Chunmin 2; Ren, Li 1; Zhu, Dexiang 1; Feng, Qingyang 1; Chang, Wenju 1; He, Guodong 1; Ye, Lechi3; Chen, Jingwen 1; Lin, Qi 1; Yi, Tuo 1; Ji, Meiling 1; Niu, Zhengchuan 1; Jian, Mi 1; Wei, Ye 1; Xu, Jianmin 1
发表日期	2018-12-31
发表期刊	JOURNAL OF ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
其他关键词	EARLY TUMOR SHRINKAGE ; COLORECTAL-CANCER ; 1ST-LINE TREATMENT ; RESISTANCE ; MUTATIONS ; KRAS ; AMPLIFICATION ; FLUOROURACIL ; LEUCOVORIN ; IRINOTECAN
摘要	Purpose. We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC). Methods. The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuximab. Next-generation sequencing was done for single nucleotide polymorphism according to custom panel. Potential predictive biomarkers were identified and integrated into a predictive model within a training cohort. The model was validated in a validation cohort. Results. Thirty-one of 247(12.6%) patients harbored RAS mutations. In training cohort (N=93), six potential predictive genes, namely, ATP6V1B1, CUL9, ERBB2, LY6G6D, PTCH1, and RBMXL3, were identified. According to predictive model, patients were divided into responsive group (n=66) or refractory group (n=27). In responsive group, efficacy outcomes were significantly improved by addition of cetuximab to chemotherapy. In refractory group, no benefit was observed. Interaction test was significant across all endpoints. In validation cohort (N=123), similar results were also observed. Conclusions. In the first-line treatment of mCRC, the predictive model integrating six new predictive mutations divided patients well, indicating a promising approach to further refine patient selection for cetuximab on the basis of RAS mutations.
资助项目	Merck KGaA [EMR 062202_272]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81602040]
出版者	HINDAWI LTD
出版地	LONDON
ISSN	1687-8450
EISSN	1687-8469
卷号	2018 页码:5072987
DOI	10.1155/2018/5072987
页数	14
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000446048400001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
Pubmed记录号	30305811
PMC记录号	PMC6165607
Scopus记录号	2-s2.0-85054312478
通讯作者地址	[Xu, Jianmin]Department of General Surgery,Zhongshan Hospital,Fudan University,Shanghai,China
scopus学科分类	Oncology
引用统计	被引频次：12[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/3991
专题	附属第一医院_肿瘤外科
通讯作者	Xu, Jianmin
作者单位	1.Department of General Surgery,Zhongshan Hospital,Fudan University,Shanghai,China; 2.Department of Anatomy,Histology and Embryology,Shanghai Medical College,Fudan University,Shanghai,China; 3.Department of Oncological Surgery,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
推荐引用方式 GB/T 7714	Zheng, Peng,Liang, Chunmin,Ren, Li,et al. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis[J]. JOURNAL OF ONCOLOGY,2018,2018:5072987.
APA	Zheng, Peng., Liang, Chunmin., Ren, Li., Zhu, Dexiang., Feng, Qingyang., ... & Xu, Jianmin. (2018). Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. JOURNAL OF ONCOLOGY, 2018, 5072987.
MLA	Zheng, Peng,et al."Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis".JOURNAL OF ONCOLOGY 2018(2018):5072987.